RhumbLine Advisers’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-77,944
| Closed | -$1.57M | – | 3034 |
|
|
2021
Q3 | $1.57M | Sell |
77,944
-1,119
| -1% | -$30.9K | ﹤0.01% | 2026 |
|
|
2021
Q2 | $2.95M | Sell |
79,063
-4,154
| -5% | -$127K | ﹤0.01% | 1743 |
|
|
2021
Q1 | $2.13M | Sell |
83,217
-5,614
| -6% | -$143K | ﹤0.01% | 1881 |
|
|
2020
Q4 | $1.96M | Sell |
88,831
-1,103
| -1% | -$24.3K | ﹤0.01% | 1857 |
|
|
2020
Q3 | $1.62M | Sell |
89,934
-12,763
| -12% | -$264K | ﹤0.01% | 1786 |
|
|
2020
Q2 | $2.61M | Buy |
102,697
+25,254
| +33% | +$544K | ﹤0.01% | 1582 |
|
|
2020
Q1 | $1.42M | Buy |
77,443
+2,639
| +4% | +$51.3K | ﹤0.01% | 1728 |
|
|
2019
Q4 | $1.65M | Buy |
74,804
+2,114
| +3% | +$42.5K | ﹤0.01% | 1869 |
|
|
2019
Q3 | $1.04M | Buy |
72,690
+527
| +0.7% | +$7.53K | ﹤0.01% | 2015 |
|
|
2019
Q2 | $1.14M | Buy |
72,163
+2,085
| +3% | +$28.4K | ﹤0.01% | 2006 |
|
|
2019
Q1 | $1.03M | Buy |
70,078
+2,886
| +4% | +$33.2K | ﹤0.01% | 2022 |
|
|
2018
Q4 | $718K | Buy |
67,192
+26,483
| +65% | +$348K | ﹤0.01% | 2143 |
|
|
2018
Q3 | $621K | Sell |
40,709
-1,892
| -4% | -$27.5K | ﹤0.01% | 2193 |
|
|
2018
Q2 | $522K | Buy |
+42,601
| New | +$535K | ﹤0.01% | 2294 |
|
|
2016
Q2 | – | Sell |
-14,463
| Closed | -$78K | – | 3043 |
|
|
2016
Q1 | $78K | Hold |
14,463
| – | – | ﹤0.01% | 2928 |
|
|
2015
Q4 | $172K | Buy |
14,463
+1,355
| +10% | +$15.5K | ﹤0.01% | 2851 |
|
|
2015
Q3 | $108K | Buy |
13,108
+593
| +5% | +$6.85K | ﹤0.01% | 2935 |
|
|
2015
Q2 | $175K | Buy |
+12,515
| New | +$230K | ﹤0.01% | 2930 |
|
Other funds holding DRNA
RhumbLine Advisers's DRNA Position: Q4 2021 in Review
RhumbLine Advisers sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 77,944 shares — an estimated $1.57M sold.
RhumbLine Advisers first reported a position in DRNA in Q2 2015 and held it in 18 quarters. The position peaked at $2.95M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- RhumbLine Advisers reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- RhumbLine Advisers sold 77,944 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.57M.
- RhumbLine Advisers first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2015 and held it in 18 quarters.
- RhumbLine Advisers's Dicerna Pharmaceuticals, Inc. position peaked at $2.95M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on RhumbLine Advisers's 13F filing for Q4 2021, filed 10 Feb 2022.